Background: Many young people with major depression fail first-line treatments. Treatment-resistant depression has various definitions in the literature but typically assumes nonresponse to medication. In young people, cognitive behavioral therapy (CBT) is the recommended first-line intervention, thus the definition of treatment resistance should be expanded. Therefore, our aim was to synthesize the existing evidence of any interventions for treatment-resistant depression, broadly defined, in children and adolescents and to investigate the effectiveness of CBT in this context.

Methods: We used Cochrane Collaboration methodology, with electronic searches of MEDLINE, PsycINFO, Embase, and the Cochrane Depression Anxiety and Neurosis Group trials registers. Only randomized controlled trials were included, and were assessed for risk of bias. Meta-analysis was undertaken where possible and appropriate.

Results: Of 953 articles retrieved, four trials were eligible for inclusion. For one study, only the trial registration document was available, because the study was never completed. All other studies were well conducted with a low risk of bias, although one study had a high dropout rate. Two studies assessed the effect of adding CBT to medication. While a strong trial of antidepressants does appear to lead to benefit, when compared with placebo, there was no significant advantage, in either study, or in a meta-analysis of data from these trials, that clearly demonstrated an additional benefit of CBT. The third trial showed little advantage of a tricyclic antidepressant over placebo in the context of an inpatient admission.

Conclusion: Few randomized controlled trials have investigated interventions for treatment-resistant depression in young people, and results from these show modest benefit from antidepressants with no additional benefit over medication from CBT. Overall, there is a lack of evidence about effective interventions to treat young people who have failed to respond to evidence-based interventions for depression. Research in this area is urgently required.

Keywords: depressive disorder, treatment-resistant, adolescence, cognitive behavioral therapy, systematic review, meta-analysis
Early onset of depressive disorder often indicates a severe illness, with high likelihood of recurrence into adulthood. Approximately 70% of adolescents with diagnosed depression will relapse within 5 years and are four times more likely to have an adult depressive disorder than adolescents who never experience a depressive episode. The duration of a major depressive episode in young people is in the range of 6–9 months. However, about 50% of children and adolescents remain clinically depressed at 12 months, and 20%–40% at 24 months.

Treatment-resistant or treatment-refractory depression is a relatively ill-defined term. Some authors consider depression is refractory to treatment after failure to respond to one adequate antidepressant trial, and others consider it as failure to respond to two adequate trials of medication. Most definitions are based on failure to respond to medication rather than to psychotherapy or other interventions. There is an array of systems that categorize different levels of nonresponse to treatment. From a client’s perspective, being relatively free of symptoms is the ultimate goal of treatment, and thus treatment-resistant depression should be defined using Frank et al’s criteria as a failure to achieve remission, which is a period of time during which “the individual is asymptomatic (ie, no longer meets syndromal criteria for the disorder and has no more than minimal symptoms).”

It must be acknowledged that the treatments currently available do not work for all young people. Failure to respond to first-line treatments with psychotherapy and psychotropic medications is common. In a review of trials of selective serotonin reuptake inhibitors (SSRIs), the response rates for those treated with fluoxetine ranged from 41% to 61%, and remission rates were even lower, ranging from 23% to 41%. This means that a large proportion of young people receiving recommended pharmacotherapy do not reach the point of remission, even when taking medication. In the field of treatment-resistant depression in adults, CBT has been investigated as an augmentation strategy. The current definitions of treatment resistance should be broadened to include failure to respond to any treatment. Studies of treatment resistance that include failure to respond to psychotherapy and other interventions are needed to ensure that a young person failing any first-line treatment receives further intervention to prevent the potential long-term negative impacts of persistent depression.

The aim of this review was to synthesize the existing evidence of any interventions for treatment-resistant depression in children and adolescents, including persisting depression after psychotherapy or medication. We have defined treatment resistance broadly, and included any trial that had as one of its aims the treatment of young people with treatment-resistant or persistent depression.

Methods

Search strategy

The MEDLINE, PsycINFO, and Embase databases were electronically searched from inception to February 2011. MEDLINE was searched using the following keywords, and where applicable, mapped onto Mesh headings: (“depression” or “depressive disorder” or “depressive disorder, major” or...
“dysthymic disorder” or “mood disorders”) (in major Mesh heading field only) AND (resistant or refractory) (in title field only) and (Adolescent or Adult or Infant+ or Child+ or Aged+ or Middle Aged) (in SubMesh heading field only) AND (clinical trial* or AB clinical trial* or MH clinical trial* or RN clinical trial* random* or AB random* or MH random* or RN random* placebo* or AB placebo* groups) in title and publication type fields only. PsychINFO and Embase were searched using similar search strings, adapted for each individual database’s search engine and Mesh headings (contact authors for full search strategies).

The Cochrane Collaboration Depression Anxiety and Neurosis Group Clinical Trials Registers (CCDAnCTR) were searched. CCDAnCTR-Studies Register was searched using the following terms: condition = (depress* and “treatment resistant”) and age group = (child* or adolescent*).

The CCDAnCTR References Register was searched using the following terms:

Title/Abstract/Keywords = (depress*) AND (adolesc* or preadolesc* or pre-adolesc* or boy* or girl* or child* or infant* or juvenil* or minors or school* or pediatri* or paediatri* or pubescen* or puberty or student* or teen* or young or youth* or school* or high-school or “high school” or college or undergrad*) AND Free-Text = (refractory or resistant*) OR (chronic* or persist*) OR (recurrent* or remiss*) OR (nonrespon* or non-respon* or “non respon”*) OR (treat* or therap*) and fail*) AND #2(link to studies) = empty.

We also searched the references of the studies included in the review. The titles and abstracts of all articles retrieved in the search were reviewed and the full text was retrieved for any articles that appeared to meet the study criteria. Any uncertainties over inclusion and exclusion were resolved by a discussion between the authors.

Inclusion criteria
We included studies that met the following criteria: any intervention designed to treat children and/or adolescents with treatment-resistant or persistant depression, as defined by the authors; study participants aged 4–18 years; and a randomized controlled trial design. There were no restrictions on language.

Data extraction
Two review authors independently extracted information on each study, including characteristics of the design, participants, intervention and comparison groups, information about the conduct of the trial in order to assess the risk of bias, and outcome data. Any discrepancies were discussed. We assessed the risk of bias in included studies using the method followed by the Cochrane Collaboration. Specifically, assessment was made of the conduct of the trial with regard to random sequence generation, allocation concealment, blinded assessment of efficacy and adverse outcomes, blinding of care providers/participants, whether the number and reasons for dropout were reported, if intent-to-treat analysis was done, and how studies were funded.

Statistical analysis
The primary outcome from the meta-analysis was a clinically meaningful response to intervention, defined as Clinically Global Impressions (CGI) improvement score ≤ 2 (much or very much improved). This is a commonly used definition of response in medication trials of young people with depression. Secondary outcomes included reduction in clinician-rated and self-rated depressive symptoms on standardized validated symptom measures. Where meta-analysis was appropriate, pooled effect estimates were obtained using the meta-analytic standard software used by the Cochrane Collaboration, ie, the Review Manager statistical software program.

For dichotomous outcomes, including response, the risk ratio and the absolute risk reduction were estimated. For continuous outcomes, such as depression symptoms, where absolute values of post-treatment means and standard deviations were given using the same rating scale across trials, these were used to calculate the mean difference, and where different rating scales were used, the standardized mean difference was used.

For all meta-analyses we used the random-effects model with a 95% confidence interval (CI). Random-effects models are in general more conservative than fixed-effects models because they take heterogeneity among studies into account. With decreasing heterogeneity, the random-effects approach moves asymptotically towards a fixed-effects model. Where meta-analysis was not appropriate, outcome data are presented in table form and results reported by the investigators are discussed in narrative form.

Results
Description of studies
In total, 953 articles were retrieved via the search of electronic databases. Of these, 910 were excluded on the basis of title and abstract. Forty-three full text articles were retrieved for closer examination, of which 27 were excluded. A total of four trials (16 articles) were included, some of which had multiple associated secondary publications.
(see Figure 1). For one study, only the trial registration document is available because the study was suspended. There are no reasons for its suspension provided, nor is it clear if recruitment ever started for this trial. The trial was to test the effectiveness of fluoxetine augmented with lamotrigine compared with sertraline in 13–17-year-olds who had not responded to 8 weeks of fluoxetine. This suspended trial will not be discussed further.

Of the remaining three studies, one tested the effectiveness of medication alone; the Adolescent Depression Antidepressants and Psychotherapy Trial (ADAPT) tested the addition of CBT to routine care plus an SSRI (primarily fluoxetine) compared with routine care plus an SSRI; and the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study included four arms, ie, venlafaxine alone, an SSRI alone, venlafaxine + CBT, and an SSRI + CBT.

The definition of “treatment resistance” varied from study to study. This is likely to have resulted in a difference in the severity of depression in participants in the different trials. In the medication only trial, young people were required to have been referred for a hospital admission due to non-response to “several psychosocial (group, individual, and family) and/or pharmacological inpatient interventions.”

**Figure 1** PRISMA flow diagram of record retrieval and inclusion and exclusion of articles.

**Abbreviations:** CCDANCTR, Cochrane Collaboration Depression Anxiety and Necrosis Group Clinical Trials Registers; RCT, randomized controlled trials.
The mean Hamilton Depression Rating Scale (HDRS) score for this group of participants was in the severe range at 22.4, with a mean index episode duration of 61 weeks. Over 40% were considered suicidal, and at least 25% of the participants had some comorbid disorder, although this is not well reported.

In the ADAPT trial, an early presentation of the study methodology described its aim as treating “persistent adolescent major depression,” with entry criteria being failure to respond, in the initial phase of the trial, to two brief initial sessions of support and educational interventions with a psychiatrist. The sample included 34 adolescents with “proven nonresponse” in that they had failed a trial of psychosocial intervention before being referred into the trial. This was a pragmatic trial conducted in tertiary specialist mental health outpatient clinics and the authors note that “Most participants had already been treated and would have received psychosocial interventions before medication.” The Children’s Depression Rating Scale-Revised (CDRS-R) scores were in the moderately severe range, with a median range of index episodes of 40 weeks; 88.5% had a comorbid disorder, around 40% in each treatment group experienced suicidal ideation, and 20% in the fluoxetine group and 12.4% in the fluoxetine + CBT group reported a previous suicide attempt during their baseline interview.

In the TORDIA study, treatment resistance was defined as a failure to respond to at least 8 weeks of treatment with an SSRI. Participants in this trial also had moderately severe depression based on CDRS-R scores, and the median duration of the index episode was approximately 68 weeks; 51.5% had at least one comorbid disorder and 58.5% had clinically significant suicidal ideation.

Both ADAPT and TORDIA were multisite studies, recruiting 208 and 334 participants, respectively. The ADAPT study recruited via routine outpatient clinical services, while TORDIA recruited via clinical sources and via advertisements. The Birmaher trial was a single-site study that recruited 27 participants from the inpatient unit in which the interventions were delivered.

The mean age of participants in the trials ranged between 14 years in the ADAPT trial and 16 years in both TORDIA and the trial by Birmaher et al. In all three trials, the percentage of females was approximately 70%. Only ADAPT and TORDIA had follow-up assessment, lasting 28 and 24 weeks, respectively. Birmaher et al conducted a 10-week acute phase with no follow-up reported. Further details of the included studies are shown in Table 1.

Methodological quality

Assessment of risk of bias

A description of the conduct of the included trials and assessment of the risk of bias is presented in Table 2. All three completed trials gave details of the randomization procedure, which was adequate in all cases, but only one, ie, ADAPT, described adequate allocation concealment. All three studies gave an explicit description of an adequate masking procedure for efficacy outcomes but an adequate masking procedure for adverse outcomes was only undertaken in one study (ADAPT). In trials that included CBT, it was not possible to blind participants and clinicians to the delivery of CBT (ADAPT and TORDIA). In the TORDIA study, after 12 weeks of acute treatment, nonresponders were entered into indicated open-label treatment, which could consist of a higher medication dose, a switch to another medication, augmentation with another medication, CBT, or other psychotherapy. However, the independent evaluator remained blinded.

The attrition rate for the three completed trials varied. It was relatively low in the ADAPT trial (6% in the fluoxetine-alone group and 10% in the fluoxetine + CBT group) compared with the TORDIA study (27%–29% in the medication-alone groups and 29%–30% in the medication + CBT groups). In the study by Birmaher et al, the attrition rate was 8% in the medication-only group compared with 36% in the placebo group. Only one trial (TORDIA) reported on reasons for dropout in sufficient detail to be able to assess whether dropouts were because of side effects of treatment or to worsening depression, and in this trial the reasons were similar across all arms of the trial. In the Birmaher trial, there were more people withdrawn from the placebo group due to worsening depression than in the medication group. Both TORDIA and the medication-only trial appeared to include all randomized patients in an intention-to-treat analysis.

The investigators in the TORDIA study reported that their study was underpowered, and while baseline characteristics were mostly similar across all treatment groups, the venlafaxine group had lower Beck Depression Inventory scores and lower rates of post-traumatic stress disorder. There was also a change part way through this study from using paroxetine to citalopram, although this did not affect many participants. It should also be noted that the analysis of outcome data was not on the basis of the way participants were randomized (in a factorial design), but rather according to whether or not they received CBT.
Table 1 Characteristics of randomized controlled trials for young people with treatment-resistant depression

<table>
<thead>
<tr>
<th>Study</th>
<th>Setting for recruitment</th>
<th>Setting for intervention</th>
<th>Definition treatment resistance</th>
<th>Inclusion and exclusion criteria (psychiatric disorders)</th>
<th>n</th>
<th>Age/ Gender</th>
<th>Duration of illness/Duration of this episode (in each group)</th>
<th>Comorbidity/ Severity of illness/ Suicide risk</th>
<th>Intervention/ Length</th>
<th>Comparison</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAPT</td>
<td>Routine outpatient clinical services in Manchester and Cambridge, UK; for the first year, four cases recruited from an adolescent inpatient unit</td>
<td>Participants were treated in routine outpatient CAMHS settings by the trial psychiatrists</td>
<td>“Persistent major depression” defined as nonresponse to 2 brief initial sessions including support and educational interventions with a psychiatrist. In addition, 34 adolescents with proven nonremitting depression (failed trial of psychosocial intervention before referral) were included.</td>
<td>Inclusion criteria: age 11–17 years and ≥4 DSM-IV depressive symptoms (including one core mood symptom of sadness, irritability, or anhedonia) during 2-week period and present on assessment plus HoNOSCA score ≥7</td>
<td>208</td>
<td>Mean: 14 years (SD 1.5) Female: 74%</td>
<td>Total median (range) index episode: 40 weeks (3–624) Fluoxetine: 52 (4–624) fluoxetine + CBT 32 (2–260)</td>
<td>92% had major depressive disorder; 8% had minor depression. Mean number of symptoms: fluoxetine + CBT 6.6 (SD 1.5); fluoxetine 6.4 (SD 1.4). CDRS-R t-scores were: total 75.0 (7.4); fluoxetine 75.3 (6.7); fluoxetine + CBT 75.1 (6.7) CDRS-R raw scores: total 58.8 (10.4); fluoxetine 59.0 (9.5); fluoxetine + CBT 58.9 (10.5)</td>
<td>Weekly CBT for 12 weeks with fortnightly sessions for an additional 12 weeks in addition to and SSRi and routine clinical care. Routine care consisted of standard interventions given to any depressed adolescent in NHS clinics: regular monitoring of mental state; psychoeducation; reflection, support and encouragement to adolescents and their families; problem solving; attention to co-morbidity; and liaison with other professionals, such as teachers and social workers</td>
<td>SRI (primarily fluoxetine, unless participant already prescribed another SRI) alone for 28 weeks in addition to routine clinical care. Fluoxetine dosage: 10 to 20 mg/day to a maximum of 60 mg/day from 6 weeks. Participants seen regularly for prescription and monitoring by study psychiatrists. Routine care consisted of standard interventions given to any depressed adolescent in NHS clinics: regular monitoring of mental state; psychoeducation; reflection, support and encouragement to adolescents and their families; problem solving; attention to co-morbidity; and liaison with other professionals, such as teachers and social workers</td>
<td>28 weeks (from baseline)</td>
</tr>
<tr>
<td>Birmaher</td>
<td>Mayview State Hospital inpatients</td>
<td>Referred for long-term hospitalization due to failing to respond to multiple-site study in outpatient clinics</td>
<td>“Nonremitting depression” defined as nonresponse to 2 brief initial sessions including support and educational interventions with a psychiatrist. In addition, 34 adolescents with proven nonremitting depression (failed trial of psychosocial intervention before referral) were included.</td>
<td>Inclusion criteria: Age: 12–18 Diagnosis: nonpsychotic major</td>
<td>27</td>
<td>Mean: 16.2 (SD 1.4) Female: 70%</td>
<td>Total mean index episode 61.2 weeks (SD 31.4) med</td>
<td>Mean HDRS was 22.4 (SD 7.3) 6 participants</td>
<td>Amitriptyline for 10 weeks Dosage: daily</td>
<td>Placebo for 10 weeks None reported</td>
<td>None reported</td>
</tr>
</tbody>
</table>
several psychosocial and/or pharmacological inpatient interventions at university or community hospitals

depressive disorder (DSM-III-R) for at least 3 months and HDRS score ≥ 15

Exclusion criteria: lifetime presence of psychotic disorder, eating disorder, bipolar I or II disorder, substance abuse within last 6 months

an 52 weeks;
AMI mean index episode 65.69 weeks (SD 26.73); placebo mean index episode 57.07 weeks (SD 35.80)

in AMI group considered suicidal; 5 participants in placebo group considered suicidal
Total comorbidity unclear, however, table 1 shows at least a quarter of participants had some comorbidity

dosage increased by 50 mg/week to a maximum of 5 mg/kg/day or 300 mg/day or amitriptyline plus NTP plasma levels no greater than 300 ng/mL. Dosage was not increased if patient showed improvement.

During the protocol patients were allowed to take lorazepam for severe agitation or insomnia. They also participated in psychosocial interventions (eg, groups, placement preparation).

Fluoxetine augmented by lamotrigine for 8 weeks

<table>
<thead>
<tr>
<th>Study</th>
<th>Setting for intervention</th>
<th>Gender</th>
<th>Setting for recruitment</th>
<th>Intervention/Length</th>
<th>Inclusion and exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robins$^{15}$</td>
<td>Primary care psychiatric outpatients</td>
<td>NA</td>
<td>Nonresponders to 8 weeks of fluoxetine, on at least 40 mg/day</td>
<td>NA NA NA NA</td>
<td>Inclusion criteria: age 13–17 years; diagnosis of major depressive episode (DSM-IV criteria) from major depressive disorder or bipolar disorder. Exclusion criteria: suicide risk defined as medically</td>
</tr>
<tr>
<td>TORDIA$^{48}$</td>
<td>Clinical sources multiple-site study in outpatient clinics</td>
<td>NA</td>
<td>Failure to respond to SSRI treatment regimen of at least 8 weeks, the last 4 of which were at a dosage of at least 40 mg/day fluoxetine (or equivalent).</td>
<td>NA 16 years, female 70%</td>
<td>Inclusion criteria: age 12–18 years; diagnosis: depressive disorder (DSM-IV) plus CDRS-R score ≥ 40 and CGI-S score ≥ 4. Exclusion criteria:</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study</th>
<th>Setting for recruitment</th>
<th>Setting for intervention</th>
<th>Inclusion and exclusion criteria (psychiatric disorders)</th>
<th>n</th>
<th>Age/Gender</th>
<th>Duration of illness/Duration of this episode (in each group)</th>
<th>Comorbidity/ Severity of illness/Suicide risk</th>
<th>Intervention/Length</th>
<th>Comparison</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>TORDIA cont.</td>
<td>Also included participants, who after attempting a dosage comparable to 40 mg/day fluoxetine could only tolerate a dose that was equivalent to 20 mg/day fluoxetine for at least 4 weeks (19/334). Note exclusion of participants with ≥ 2 failed trials of SSRIs or history of nonresponse to venlafaxine or to CBT (≤ 7 sessions)</td>
<td>bipolar spectrum disorders; psychoses; pervasive developmental disorders or autism; eating disorders; substance abuse of dependence</td>
<td>CBT groups (mean): 59.9 (SD 10.6)</td>
<td>Non-CBT groups (mean): 22.6 (SD 21.4)</td>
<td>Venlafaxine groups (mean CDRS-R): 57.8 (SD 10.1) CBT groups (mean CDRS-R): 58.4 (SD 9.7)</td>
<td>Non-CBT groups (mean CDRS-R): 59.2 (SD 11.0)</td>
<td>72.1% first episode 58.5% clinically significant suicidal ideation 51.5% had at least one comorbid disorder, the majority of which were anxiety disorders or dysthymia</td>
<td>maximum of 60 mg/day thereafter. For venlafaxine dosages for weeks 1 to 4 were 7.5, 75, 112.5, and 150 mg with option to increase to 225 mg at week 6. Pharmacotherapy sessions were between 30 and 60 minutes; conducted by psychiatrists or master's degree level nurses supervised by psychiatrist; consisted of safety assessment and occurred weekly for 4 weeks and biweekly thereafter. All participants received family psychoeducation at intake, 6-week midpoint and 12-week end of acute treatment</td>
<td>Therapists were at least master's level with experience in CBT. CBT drew on manuals that emphasize cognitive restructuring and behavioral activation, emotion regulation, social skills and problem solving; and that also emphasize parent-child sessions to decrease criticism and improve support, family communication and problem solving. Modules were flexibly applied depending on clinical need</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CBT, cognitive behavioral therapy; SSRIs, selective serotonin reuptake inhibitors; SD, standard deviation; CGI, Clinical Global Impression; CDRS-R, Children’s Depression Rating Scale-Revised; HoNOSCA, Health of the Nation Outcome Scales for Children and Adolescents; DSM, Diagnostic and Statistical Manual of Mental Disorders; CAMHS, Child and Adolescent Mental Health Service; NHS, National Health Service.
In ADAPT, the study psychiatrists delivered both arms of the intervention, raising the possibility of cross contamination. Routine treatment in both groups included some elements of CBT. There were also additional interventions received as part of routine care, the details of which were not recorded. None of the three completed studies had pharmaceutical funding. Details of the included studies are included in Table 2.

**Effects of medical interventions**

**Medication versus placebo**

One trial examined the effects of a medication (amitriptyline, a tricyclic antidepressant) compared with a placebo for participants who had not responded to previous interventions, which included tricyclic antidepressants, sertraline, paroxetine or fluvoxamine, and lithium. Data for this trial are presented in Table 3.

**Response**

The trial authors reported that there was no difference between groups in response, with similar numbers no longer fulfilling criteria for major depressive disorder at the end of the study. At the end of the treatment period, 30% continued to fulfill criteria for major depressive disorder and about 60% continued to have subsyndromal symptoms. The trial authors report that only an initial self-rated depression score on the Beck Depression Inventory (BDI) predicted response. The investigators also reported that the medication and placebo groups demonstrated similar decreases in the HDRS, and that the two groups had similar decreases in self-rated BDI scores, with no significant difference between the medication and placebo groups.

**Addition of CBT**

There were two studies that tested the effectiveness of adding CBT to a medication regimen and some data from these trials could be combined in meta-analysis. It should be noted that the data for the TORDIA study were not presented by the group to which participants were originally assigned, rather results were presented according to whether participants received CBT or not. In the group receiving medication only, approximately half received an SSRI and half received venlafaxine.

**Response**

For response, we used the definition of a CGI score ≤ 2 (much or very much improved). Based on this definition, the response rates were 43.5% in the ADAPT study and 47.6% in the TORDIA study in the groups who received no additional CBT and 42% in the ADAPT study and 59% in the TORDIA study in those groups who did receive CBT (see Table 3). This equated to a 2% risk difference between the group who received CBT and the group who did not in the ADAPT study, and an 11% risk difference between the group who received CBT and the group who did not in the TORDIA study. This difference was not significant when data from both studies were combined (relative risk 0.89, 95% CI 0.69–1.15, see Figure 2). The ADAPT study included a 28-week follow-up and showed no significant differences between the groups.

Our definition of response was the same as that used in the ADAPT study, and our results are consistent with their reporting. However, the TORDIA study authors defined response as a CGI score < 2 and 50% improvement in CDRS-R scores, and found a significantly higher rate of response in the group who received CBT (54.8%) compared with those who did not (40.5%). The authors reported that depression severity at baseline was the strongest predictor of nonresponse.

In the ADAPT study, the primary outcome variable was Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA). Using this scale, the authors reported nearly identical response rates, with 96% of young people who received CBT and 98% of those who did not receive CBT responding over 12 weeks. In the longer report of the ADAPT study, the authors defined response as a CGI score ≤ 3. Based on this definition, they report that 80% of the participants responded by 28 weeks of follow-up, and estimated that only about 10% of the trial participants were nonresponders, labeling this group “truly treatment-resistant.” They did not report an analysis of predictors of nonresponse. In a meta-analysis of response data using the TORDIA study definition and the ADAPT HoNOSCA definition of response, there was no differences between those who received CBT and those who did not (relative risk 0.86, 95% CI 0.39–1.92).

**Clinician-rated depression symptoms**

There were no significant differences between groups in clinician-rated depression severity using the CDRS-R (mean difference 0.30, 95% CI −3.85 to 3.26) post intervention (see Figure 3). The ADAPT trial reported 28-week follow-up, and there continued to be no significant differences between the groups. The results of the meta-analysis are consistent with the way the results were reported by the individual studies included in the meta-analysis with regard to clinician-reported severity of depression.
Table 2 Risk of bias

<table>
<thead>
<tr>
<th>Study</th>
<th>Randomization procedure</th>
<th>Allocation concealment</th>
<th>Blinding of outcome assessor (efficacy outcomes)</th>
<th>Blinding of outcome assessor (adverse outcomes)</th>
<th>Blinding of participants/care givers</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAPT47</td>
<td>Adequate: Stochastic minimization was used to ensure balance on severity, center, sex, comorbid behavioral disorder (probable or definite oppositional defiant disorder or conduct disorder) and age. Page 15 HTA report51</td>
<td>Adequate: The study psychiatrist telephoned an independent centre, the Department of Medical Statistics at the Christie Hospital in Manchester, for randomization. Page 15 HTA report51</td>
<td>Adequate: Outcome assessments were done by independent evaluators blind to treatment assignment. Specific instructions were given to participants, parents, and treating clinicians not to disclose treatment assignment to the blinded evaluator. Page 15 HTA report51</td>
<td>Adequate: Adverse events were recorded at each assessment interview (which were conducted by blind outcome assessors). Page 10 HTA report51</td>
<td>Inadequate: Study compared CBT with non-CBT, therefore participants and study clinicians could not be blind to treatment</td>
</tr>
<tr>
<td>Birmaher46</td>
<td>Adequate: “[R]andomly assigned using a modification of Efon’s biased coin toss to match approximately for age and gender.” Page 528</td>
<td>Clear: No detail</td>
<td>Adequate: Psychiatric research nurse administered outcome measurement. “To maintain blindness of treatment assignment, the research nurse was unaware of the results of the side effect evaluations.” Page 529</td>
<td>Inadequate: The only nonblind investigator monitored patients’ responses to treatment, AMI doses, and presence of side effects. This investigator was not involved in any of the ratings of the patient.” Page 529</td>
<td>Clear: States blinding will be maintained by the comparison group receiving a placebo augmentation</td>
</tr>
<tr>
<td>Robins6</td>
<td>Unclear: No detail</td>
<td>Unclear: No detail</td>
<td>Inadequate: States blinding will be maintained by the comparison group receiving a placebo augmentation</td>
<td>Inadequate: “[T]he intent was for study participants, clinicians, and independent evaluators to be blinded to medication treatment assignment and for independent evaluators to be blinded to CBT assignment. Blinding for medication was maintained by use of 3 encapsulated pills daily for all prescriptions, some of which might be placebo to mask drug type and dose. The blinding to CBT for independent evaluators was maintained by scheduling the independent evaluator’s assessments at a time not contiguous with CBT sessions and by asking participants and staff not to discuss CBT treatment assignment when the independent evaluator was present. In 64 cases, the blinding of the independent evaluator was compromised, most commonly because of participant disclosure of receiving CBT. Page 904</td>
<td>Inadequate: “The intent was for study participants, clinicians, and independent evaluators to be blinded to medication treatment;” however they were not blind to CBT assignment. Page 904</td>
</tr>
<tr>
<td>TORDIA48</td>
<td>Adequate: “[U]sing a variation of Efon’s biased coin toss” page 904 Note: The study randomized participants to an SSRI depending on what SSRI they were already on; ie, it had to be a switch to another SSRI</td>
<td>Unclear: No detail</td>
<td>Adequate: The intent was for study participants, clinicians, and independent evaluators to be blinded to medication treatment assignment and for independent evaluators to be blinded to CBT assignment. Blinding for medication was maintained by use of 3 encapsulated pills daily for all prescriptions, some of which might be placebo to mask drug type and dose. The blinding to CBT for independent evaluators was maintained by scheduling the independent evaluator’s assessments at a time not contiguous with CBT sessions and by asking participants and staff not to discuss CBT treatment assignment when the independent evaluator was present. In 64 cases, the blinding of the independent evaluator was compromised, most commonly because of participant disclosure of receiving CBT. Page 904</td>
<td>Inadequate: Clinicians did the safety assessments and “[t]he intent was for study participants, clinicians, and independent evaluators to be blinded to medication treatment”; however they were not blind to CBT assignment. Page 904</td>
<td>Inadequate: “The intent was for study participants, clinicians, and independent evaluators to be blinded to medication treatment;” however they were not blind to CBT assignment. Page 904</td>
</tr>
<tr>
<td>Withdrawals n (%) in each group</td>
<td>Withdrawals due to treatment in each group</td>
<td>Intention to treat analysis</td>
<td>Other</td>
<td>Funding</td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------------------------------------</td>
<td>-----------------------------</td>
<td>-------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td><strong>Adequate:</strong> Fluoxetine alone</td>
<td>Unclear: Not enough detail provided about reasons for drop out by group</td>
<td>Adequate: Stated to be done on page 529 and table 2 includes all participants randomized. Note authors also undertook completer analysis, analysis of patients who completed at least 4 weeks of treatment, and stated there was no difference in outcome. Page 529</td>
<td>Unclear: 1. Study psychiatrists delivered intervention in both arms so cross contamination is possible 2. Routine care stated to include principles of CBT treatment were part of routine clinical care; however, care mainly took the form of advice, rather than collaborative goal setting, homework, rewards, and exploration and challenging of negative cognitions. Sessions were shorter and fewer 3. Precise details of any additional routinely offered CAMHS services were not systematically assessed</td>
<td>Adequate: There was no commercial sponsorship. Page 51 HTA report</td>
<td></td>
</tr>
<tr>
<td>Week 12: 6/103 (6%)</td>
<td>Fluoxetine + CBT 101/103</td>
<td>Adequate: Included in primary endpoint analysis: Fluoxetine 101/103</td>
<td>Adequate: 1. Small study 2. Previous treatment ascertained from medical records, raising the possibility of incomplete or inaccurate information, meaning the population may not truly be treatment resistant</td>
<td>Adequate: NIMH grant</td>
<td></td>
</tr>
<tr>
<td>Week 28: 13/103 (13%)</td>
<td>Fluoxetine alone 101/103</td>
<td>Adequate: Stated to be done</td>
<td>Adequate: Study suspended</td>
<td>Adequate: GlaxoSmithKline</td>
<td></td>
</tr>
<tr>
<td>Fluoxetine + CBT</td>
<td>Adequate: Ami: 1/13 (8%) Placebo: 5/14 (36%) Ami: 1 Placebo: 5 Page 530</td>
<td>Adequate: Figure page 903 and table 2 page 907 indicate all randomized were analyzed; with both intent-to-treat and observed case data presented. State LOCF data were used</td>
<td>Adequate: 1. There was a change part way through the study from using to paroxetine (due to concerns about efficacy and safety) to citalopram. Of the 50 randomized to receive paroxetine only three were in active treatment at the time of the change and were removed from the study. 2. Did not meet target recruitment to satisfy power calculation (required 400 participants). 3. Baseline characteristics are not reported by intervention group; authors report no significant differences between groups, with the exception that the venlafaxine group had lower Beck Depression Inventory score and lower rates of PTSD</td>
<td>Adequate: National Institute of Mental Health</td>
<td></td>
</tr>
<tr>
<td>Week 12: 11/105 (10%)</td>
<td>Unclear: No detail</td>
<td>Adequate: 1. There was a change part way through the study from using to paroxetine (due to concerns about efficacy and safety) to citalopram. Of the 50 randomized to receive paroxetine only three were in active treatment at the time of the change and were removed from the study. 2. Did not meet target recruitment to satisfy power calculation (required 400 participants). 3. Baseline characteristics are not reported by intervention group; authors report no significant differences between groups, with the exception that the venlafaxine group had lower Beck Depression Inventory score and lower rates of PTSD</td>
<td>Adequate: National Institute of Mental Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 28: 18/105 (17%)</td>
<td><strong>Inadequate:</strong> Withdrawn from study due to worsening of clinical symptoms: Ami: 1 Placebo: 5 Page 530</td>
<td>Adequate: Stated to be done on page 529 and table 2 includes all participants randomized. Note authors also undertook completer analysis, analysis of patients who completed at least 4 weeks of treatment, and stated there was no difference in outcome. Page 529</td>
<td>Adequate: There was no commercial sponsorship. Page 51 HTA report</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NA</td>
<td>Adequate: Drained from study due to worsening of clinical symptoms: Ami: 1 Placebo: 5 Page 530</td>
<td>Adequate: Figure page 903 and table 2 page 907 indicate all randomized were analyzed; with both intent-to-treat and observed case data presented. State LOCF data were used</td>
<td>Adequate: 1. There was a change part way through the study from using to paroxetine (due to concerns about efficacy and safety) to citalopram. Of the 50 randomized to receive paroxetine only three were in active treatment at the time of the change and were removed from the study. 2. Did not meet target recruitment to satisfy power calculation (required 400 participants). 3. Baseline characteristics are not reported by intervention group; authors report no significant differences between groups, with the exception that the venlafaxine group had lower Beck Depression Inventory score and lower rates of PTSD</td>
<td>Adequate: National Institute of Mental Health</td>
<td></td>
</tr>
<tr>
<td><strong>Inadequate:</strong></td>
<td>Adequate:</td>
<td>Adequate: Figure page 903 and table 2 page 907 indicate all randomized were analyzed; with both intent-to-treat and observed case data presented. State LOCF data were used</td>
<td>Adequate: 1. There was a change part way through the study from using to paroxetine (due to concerns about efficacy and safety) to citalopram. Of the 50 randomized to receive paroxetine only three were in active treatment at the time of the change and were removed from the study. 2. Did not meet target recruitment to satisfy power calculation (required 400 participants). 3. Baseline characteristics are not reported by intervention group; authors report no significant differences between groups, with the exception that the venlafaxine group had lower Beck Depression Inventory score and lower rates of PTSD</td>
<td>Adequate: National Institute of Mental Health</td>
<td></td>
</tr>
<tr>
<td><strong>NA</strong></td>
<td>Adequate:</td>
<td>Adequate: Figure page 903 and table 2 page 907 indicate all randomized were analyzed; with both intent-to-treat and observed case data presented. State LOCF data were used</td>
<td>Adequate: 1. There was a change part way through the study from using to paroxetine (due to concerns about efficacy and safety) to citalopram. Of the 50 randomized to receive paroxetine only three were in active treatment at the time of the change and were removed from the study. 2. Did not meet target recruitment to satisfy power calculation (required 400 participants). 3. Baseline characteristics are not reported by intervention group; authors report no significant differences between groups, with the exception that the venlafaxine group had lower Beck Depression Inventory score and lower rates of PTSD</td>
<td>Adequate: National Institute of Mental Health</td>
<td></td>
</tr>
<tr>
<td>Adequate: Venlafaxine alone 22/83 (27%)</td>
<td>Adequate: Venlafaxine alone Side effect: 9 Worsening depression: 3</td>
<td>Adequate: Figure page 903 and table 2 page 907 indicate all randomized were analyzed; with both intent-to-treat and observed case data presented. State LOCF data were used</td>
<td>Adequate: 1. There was a change part way through the study from using to paroxetine (due to concerns about efficacy and safety) to citalopram. Of the 50 randomized to receive paroxetine only three were in active treatment at the time of the change and were removed from the study. 2. Did not meet target recruitment to satisfy power calculation (required 400 participants). 3. Baseline characteristics are not reported by intervention group; authors report no significant differences between groups, with the exception that the venlafaxine group had lower Beck Depression Inventory score and lower rates of PTSD</td>
<td>Adequate: National Institute of Mental Health</td>
<td></td>
</tr>
<tr>
<td>Venlafaxine + CBT 30/83 (36%)</td>
<td>Venlafaxine + CBT Side effect: 10 Worsening depression: 4</td>
<td>Adequate: Figure page 903 and table 2 page 907 indicate all randomized were analyzed; with both intent-to-treat and observed case data presented. State LOCF data were used</td>
<td>Adequate: 1. There was a change part way through the study from using to paroxetine (due to concerns about efficacy and safety) to citalopram. Of the 50 randomized to receive paroxetine only three were in active treatment at the time of the change and were removed from the study. 2. Did not meet target recruitment to satisfy power calculation (required 400 participants). 3. Baseline characteristics are not reported by intervention group; authors report no significant differences between groups, with the exception that the venlafaxine group had lower Beck Depression Inventory score and lower rates of PTSD</td>
<td>Adequate: National Institute of Mental Health</td>
<td></td>
</tr>
<tr>
<td>SSRI alone 25/85 (29%)</td>
<td>SSRI alone Side effect: 9 Worsening depression: 3</td>
<td>Adequate: Figure page 903 and table 2 page 907 indicate all randomized were analyzed; with both intent-to-treat and observed case data presented. State LOCF data were used</td>
<td>Adequate: 1. There was a change part way through the study from using to paroxetine (due to concerns about efficacy and safety) to citalopram. Of the 50 randomized to receive paroxetine only three were in active treatment at the time of the change and were removed from the study. 2. Did not meet target recruitment to satisfy power calculation (required 400 participants). 3. Baseline characteristics are not reported by intervention group; authors report no significant differences between groups, with the exception that the venlafaxine group had lower Beck Depression Inventory score and lower rates of PTSD</td>
<td>Adequate: National Institute of Mental Health</td>
<td></td>
</tr>
<tr>
<td>SSRI + CBT 25/83 (30%)</td>
<td>SSRI + CBT Side effect: 13 Worsening depression: 2</td>
<td>Adequate: Figure page 903 and table 2 page 907 indicate all randomized were analyzed; with both intent-to-treat and observed case data presented. State LOCF data were used</td>
<td>Adequate: 1. There was a change part way through the study from using to paroxetine (due to concerns about efficacy and safety) to citalopram. Of the 50 randomized to receive paroxetine only three were in active treatment at the time of the change and were removed from the study. 2. Did not meet target recruitment to satisfy power calculation (required 400 participants). 3. Baseline characteristics are not reported by intervention group; authors report no significant differences between groups, with the exception that the venlafaxine group had lower Beck Depression Inventory score and lower rates of PTSD</td>
<td>Adequate: National Institute of Mental Health</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** AMi, amitriptyline; CBT, cognitive behavioral therapy; HTA, Health Technology Assessment; LOCF, last observation carried forward; PTSD, posttraumatic stress disorder; SSRI, selective serotonin reuptake inhibitor.
Self-rated depression symptoms
There were no significant differences between the groups in self-rated depression severity on the BDI and Mood and Feelings Questionnaire (standardized mean difference $-0.06$, 95% CI $-0.23$–$-0.11$) post intervention (see Figure 4), or at 28-week follow-up in the one trial (ADAPT) in which this was reported. The results of the meta-analysis are consistent with the way results were reported by the individual studies that were included in the meta-analysis with regard to self-reported depression severity.

Discussion
Principal findings
In our systematic review, we identified only three studies investigating the management of broadly defined treatment-resistant depression in young people. Two of these assessed medication and the effect of adding CBT to medication. While an assertive trial of medication showed some benefit, particularly in one study, neither study nor a meta-analysis of data from two trials clearly demonstrated an additional benefit of CBT over and above the medication regimens already in place for any outcome. It should be noted that there was no placebo arm in either of these studies. The third trial showed no advantage of a tricyclic antidepressant over placebo in the context of an inpatient admission. The studies were well conducted with a low risk of bias, although the TORDIA study did have very high dropout rates. There were no trials of CBT alone or of other psychotherapies, such as interpersonal therapy. Overall, there is currently little evidence upon which to base clinical decisions about interventions for treatment-resistant depression in young people.

Strengths and limitations
To our knowledge, no other systematic review or meta-analysis of interventional studies for treatment of resistant depression in children and adolescents has been published. We used Cochrane Collaboration methodology, which ensures clarity and includes an assessment of the possible risk of bias in each study included in the review.

We used a broad definition of treatment resistance to ensure that we included as many clinically meaningful data as possible. However, given the paucity of studies in this area, and the variable definitions of treatment resistance that

### Table 3 Outcome data

<table>
<thead>
<tr>
<th>Study</th>
<th>Response data (CGI = 2)</th>
<th>Response data (trial definition)</th>
<th>Clinician-rated depression</th>
<th>Self-rated depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAPT</td>
<td>12 weeks</td>
<td>12 week (HoNOSCA – criteria not defined)</td>
<td>12 weeks CDRS-R</td>
<td>12 weeks MFQ</td>
</tr>
<tr>
<td></td>
<td>28 weeks</td>
<td>28 weeks (HoNOSCA – criteria not defined)</td>
<td>CBT 4.2 (16.8)</td>
<td>CBT 22.7 (15.4)</td>
</tr>
<tr>
<td></td>
<td>CBT 42/101 (42%)</td>
<td>CBT 9/101 (96%)</td>
<td>CBT 40.0 (13.9)</td>
<td>No CBT 21.6 (14.8)</td>
</tr>
<tr>
<td></td>
<td>No CBT 44/101 (43.5%)</td>
<td>No CBT 99/101 (98%)</td>
<td>CBT 36.4 (15.3)</td>
<td>CBT 18.9 (15.5)</td>
</tr>
<tr>
<td></td>
<td>28 weeks</td>
<td>28 weeks (HoNOSCA – criteria not defined)</td>
<td>No CBT 87/95 (92%)</td>
<td>No CBT 34.6 (13.4)</td>
</tr>
<tr>
<td>Birmaher</td>
<td>10 weeks</td>
<td>10 weeks ($\geq 50%$ reduction in HDRS)</td>
<td>10 week HDRS</td>
<td>10 week BDI</td>
</tr>
<tr>
<td></td>
<td>Medication 10/13 (77%)</td>
<td>Medication 10/13 (77%)</td>
<td>Medication 7.7 (8.0)</td>
<td>Medication 10.1 (11.8)</td>
</tr>
<tr>
<td></td>
<td>Placebo 8/14 (57%)</td>
<td>Placebo 11/14 (79%)</td>
<td>Placebo 8.6 (11.5)</td>
<td>Placebo 10.1 (11.1)</td>
</tr>
<tr>
<td>TORDIA</td>
<td>12 weeks</td>
<td>12 weeks (CGI $\leq 2 + \geq 50%$ improvement in CDRS-R)</td>
<td>12 weeks CDRS-R</td>
<td>12 weeks BDI CBT</td>
</tr>
<tr>
<td></td>
<td>CBT 98/166 (59.0%)</td>
<td>CBT 91/166 (54.8%)</td>
<td>CBT 36.9 (13.9)</td>
<td>CBT 11.0 (11.5) BDI</td>
</tr>
<tr>
<td></td>
<td>24 weeks</td>
<td>24 weeks</td>
<td>CBT 38.1 (12.9)</td>
<td>No CBT 10.5 (9.8)</td>
</tr>
<tr>
<td></td>
<td>Not reported</td>
<td>Not reported</td>
<td>No CBT 68/168 (40.5%)</td>
<td>No CBT 68/168 (40.5%)</td>
</tr>
</tbody>
</table>

### Abbreviations
- BDI, Beck Depression Inventory; CBT, cognitive behavioral therapy; CDRS-R, Children’s Depression Rating Scale-Revised; HoNOSCA, Health of the Nation Outcome Scales for Children and Adolescents; MFQ, Mood and Feelings Questionnaire.
were used in each study, we had to be cautious about how we compared the trials in this review.

As is often the case, establishing the most meaningful outcome across diverse studies is a challenge. We used the CGI criteria as our primary outcomes measure. The CGI scale provides a relatively crude estimate of treatment response. We used this measure because data based on this definition were available from both trials, providing some consistency, and because the CGI has been used as a primary outcome variable in a number of studies of treatment of depression and because the CGI has been used as a primary outcome variable in a number of studies of treatment of depression in children and adolescents. However, because of the potential limitations of the measure, we also carried out a meta-analysis of response based on the definitions of response in the individual trials (CGI plus CDRS-R for the TORDIA study, and response on HoNOSCA data for the ADAPT study). Although there was a more favorable response rate in those who received additional CBT in the TORDIA study, when findings were aggregated with ADAPT, this finding was not supported.

It is of note that the differences reported in the TORDIA study are relatively small and not maintained at follow-up (according to rates of remission, which were 36.7% in those who received additional CBT and 41.1% in those who did not). There were also no significant differences on other outcomes, there were high dropout rates, and the results were not reported according to the groups participants were allocated to, but rather according to whether they received CBT or not. Therefore, post intervention results with regard to response rates should be interpreted cautiously.

Our finding that CBT confers no additional benefit to medication is consistent with findings from two previous studies of young people with depression (although not classed as treatment-resistant). A randomized effectiveness trial of adolescents with major depressive disorder of moderate severity, who had recently been prescribed an SSRI, showed only weak effects of additional CBT. In the Treatment for Adolescents with Depression Study (TADS), while the group on combined medication and CBT improved more than those on either CBT or fluoxetine alone in the short term, by 36 weeks there was no difference between groups, and a reanalysis of the TADS data showed that combined treatment did not offer any advantage in those participants who were most impaired.

### Clinical implications

Unfortunately many young people do not respond to initial treatment for depression. The move to an assertive trial of an antidepressant does appear to lead to benefit, especially in the ADAPT trial, although it should be noted that previous treatment in this trial was predominantly psychosocial. In the medication only study, Birmaher et al hypothesized that young people recovered regardless of the group they were in due to the effect of removing them from their environment into an inpatient setting, potentially decreasing the stress they had been experiencing, stating the entire sample came from “disorganized and conflict-ridden families.” The authors of this trial (Birmaher et al) also hypothesized that the improvement in symptoms that participants in this trial experienced might have been due to them receiving positive attention from the research nurse who also motivated the participants to remain in the study. In the TORDIA study, pharmacotherapy sessions were 30–60 minutes in length and...
consisted mostly of safety assessments, but participants also received family psychoeducation sessions at the beginning, midpoint, and end of the intervention period. In the ADAPT trial, which was a pragmatic trial by design, the participants were all receiving standard care, which included routine monitoring, psychoeducation, support, and encouragement to the young person and their families, problem-solving, attention to comorbidity, and liaison with schools and social workers as required. From these studies, it is impossible to know whether CBT on its own may lead to improvement for treatment-resistant young people, or whether CBT should be started first and medication added if the need arose.

Both the TORDIA study and the study of medication only showed that nonresponse to the interventions was predicted by more severe symptoms. Therefore, and consistent with guideline recommendations, CBT may be best reserved for first-line intervention. We propose that treatment resistance should be defined as a failure to respond to an adequate trial of an evidence-based psychological intervention, followed by a failure to respond to the addition of an adequate trial of fluoxetine.

An adequate trial of an intervention such as CBT needs to be more clearly articulated. The lack of effectiveness of additional CBT shown in the studies included in this review may, for example, be due to the “dose” of CBT that was received. Both ADAPT and TORDIA comment on the relatively small number of CBT sessions that young people in the study received, highlighting that in this population CBT was difficult to deliver, and perhaps to receive, in this treatment group. Again, a secondary analysis of the TORDIA dataset showed that those who received fewer than nine sessions of CBT were less likely to respond. It has been argued that there is a “dose × technique” minimum threshold for the core components of CBT. It may be that, especially for those with more severe depression, an adequate response to medication is required before a young person can properly engage in psychotherapy.

Unanswered questions and future research
A significant proportion of young people in this study did not respond to any treatment. In the trial by Birmaher et al, 30%–40% still had symptoms and functional impairment at the end of the trial. Our study shows nonresponse rates of 40%–60%. In the ADAPT study, authors suggest that from the HoNOSCSA scores, nonresponse rates were as low as 10%. However, this percentage does not include a significant proportion of their participants who had only minimal improvement (around 27% at 12 weeks and 22% at 28 weeks). It is certainly the case that for a proportion of young people, existing evidence-based treatments are not sufficient and new approaches are required. There are several avenues that could be pursued further. It is possible that younger populations prefer and respond to interventions that have less emphasis on the cognitive components of CBT. Analysis of the TADS study suggests that young people respond to more simple models of CBT that focus on one or two core components, such as behavior activation and problem solving. A meta-analysis of psychotherapy for children and adolescents has shown that “noncognitive” aspects of CBT (such as behavioral activation, problem-solving, group support, and social skills training) were equally effective in treating depression, so that targeting of specific cognitions may not be necessary. Indeed, a secondary analysis of data from the TORDIA study showed that CBT participants who received the problem-solving and social skills component of CBT were more likely to respond. What has not been tested in a pragmatic trial is the effectiveness of adding CBT to standard care for young people similar to those participants in ADAPT who had severe, complex, and persistent depression.

Overall, this review highlights the need for different and more effective therapies for depression in young people. Existing therapies can cure some, and provide some help to many, but a disturbing percentage appear to get little relief from treatment currently available.

Conclusion
In two well-conducted studies, the addition of CBT to a medication regimen offered no benefit over and above the medication regimen. Overall, there is a lack of evidence about effective interventions to treat young people who have failed to respond to evidence-based interventions for depression. CBT should be reserved for first-line intervention, ensuring an adequate dose delivered over an extended period of time. In order to avert long-term disability associated with multiple episodes of illness, or persistent depression, research in this area is urgently required. Such studies should be distinct from standard maintenance phases in randomized controlled trials, and involve re-randomization of treatment nonresponders with studies large enough to have power to show differences. The challenges of conducting such studies are considerable.
Acknowledgment

We would like to thank the Cochrane Depression, Anxiety, and Neurosis Group for conducting the searches of their trials registers.

Disclosure

The authors report no conflicts of interest in this work.

References


15. Harrington RC. Adolescent depression: same or different. *Arch Gen Psychiatry*. 2001;58:21–22.


